|
|
||||||||
Stem Cells, Vol 12, 378-385, Copyright © 1994 by AlphaMed Press
REVIEWS |
D Banerjee, SC Zhao, MX Li, BI Schweitzer, S Mineishi and JR Bertino
Molecular Pharmacology and Therapeutics Program, Memorial Sloan- Kettering Cancer Center, New York, New York 10021.
The generation of drug resistant bone marrow may facilitate the development of aggressive chemotherapeutic regimens that might otherwise be lethal due to marrow toxicity. With the availability of technology that permits in vitro manipulation of human marrow and peripheral blood stem cells, it is now possible to introduce genes that confer drug resistance to these hematopoietic progenitors. Animal models and in vitro work with human progenitors using drug resistance genes are reviewed.
This article has been cited by other articles:
![]() |
J. A. Moscow, H. Huang, C. Carter, K. Hines, J. Zujewski, G. Cusack, C. Chow, D. Venzon, B. Sorrentino, Y. Chiang, et al. Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy Blood, July 1, 1999; 94(1): 52 - 61. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Licht, F. Herrmann, M.M. Gottesman, and I. Pastan In Vivo Drug-Selectable Genes: A New Concept in Gene Therapy Stem Cells, March 1, 1997; 15(2): 104 - 111. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
